Primary ovarian sarcomas are very rare tumours and are characterized by poor prognosis. Surgical treatment is mainly based on epithelial ovarian cancer debulking approaches, while chemotherapy is based on data extrapolation from studies in sarcomas of other primary sites. Trabectedin has been established as a standard of care for the treatment of soft-tissue sarcomas in the 2nd line setting. So far, no data from randomized clinical trials support specific maximum number of cycles of trabectedin for any gynaecological sarcoma. Moreover, limited evidence in the literature supports the feasibility and safety of trabectedin administration in haemodialyzed patients.
Introduction

Primary ovarian sarcomas
Primary ovarian sarcomas are very rare malignant solid tumors of mesenchymal histology, characterized by limited response to platinum-based chemotherapy and lower progression-free and overall survival compared to epithelial ovarian cancers [1] . Based on the latest WHO classification they are divided in: 1) malignant mesenchymal ovarian tumors which include low and high-grade Endometrial Stromal Sarcoma (ESS) 2) mixed mesenchymal and epithelial malignant tumors including adenosarcomas and carcinosarcomas (exmalignant mixed mullerian tumors) [2] .
Other primary ovarian sarcomas, like leiomyosarcomas and rhabodmyosarcomas can be classified either as their primary uterine counterparts or as abdominal Soft Tissue Sarcoma (STS) [3] .
The most frequent ovarian sarcoma is mixed mullerian tumor/ carcinosarcoma accounting for 1-4% of primary ovarian cancer with an incidence of 0.19/ 100,000 women [4] . Prognosis is poorer than epithelial ovarian cancer with a median survival of 18 months [5] . Reports of patients surviving over 46 months underline the importance of optimal debulking followed by ifosfamide/ cisplatin or platinum-based chemotherapy [6] . Other ovarian sarcoma types are considered very rare, accounting for approximately 1% of primary ovarian cancer [7] and include angiosarcoma, rhabdomyosarcoma, endometrial stromal sarcoma and fibrosarcoma.
Trabectedin
Trabectedin is an antineoplastic agent that was initially extracted from the marine tunicate species Esteinascidia turbinata. Its mechanism of action involves direct interference with the minor DNA groove, induction of apoptosis and inhibition of the expression of FUS-CHOP, EWS-CHOP and other transcriptional factors that act as oncogene products and immunomodulatory and anti-inflammatory activity [8] [9] [10] . Currently, trabectedin is used as 2 nd line therapy and beyond for advanced STS. Initial approval was granted in 2007 in Europe, for administration in advanced STS patients progressing on/ or being ineligible for anthracycline and ifosfamide therapy. Phase 2 clinical trial results showed a median duration of survival of 9.2 months and comparable PFS to standard chemotherapy regimens in pretreated patients [11] . Subsequently, approval was granted in the USA in 2015 for patients with advanced pretreated L-STS, including uterine LMS. 
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In pretreated patients with advanced/ metastatic L-STS, treatment with trabectedin showed notable efficacy and favorable toxicity profile at a dose of 1.5 mg/m 2 through 24-hour continuous intravenous infusion q3w achieving superior disease control compared to a dose of 0.58 mg/m 2 3-hour intravenous infusion d1, d8, d15 q4w [12] .
Subsequently, the dose of 1.5 mg/m 2 through 24-hour continuous infusion q3w exhibited significantly longer PFS Treatment has been overall well tolerated with mild hematological toxicity managed with a 25% dose reduction plus filgrastim-48mU, S:1 × 1 for 5 days after recurrent uncomplicated grade 3 neutropenia. 
Case Presentation
Discussion
Real-life data of trabectedin in STS treatment are indicative of similar or even better outcomes than the original clinical trials that led to drug approval in terms of PFS and OS. These findings vary in efficacy with ORR of 37.8%, cycles before presenting with disease progression. In both cases, low dialysis clearance, as well as the absence of detectable trabectedin in the dialysate samples, implies that trabectedin is not efficiently cleared either by hemodialysis, or by peritoneal dialysis.
The present case indicates that durable complete responses can be achieved with trabectedin therapy in such patients. In this regard, more pharmacokinetic studies are needed, as cancer incidence and recurrence are high in end-stage kidney disease patients and trabectedin appears to be an attractive option for sarcoma treatment in this group.
